Development of a high-yield reassortant influenza vaccine virus derived from the A/Anhui/1/2013 (H7N9) strain

• Published in: Vaccine Vol. 34; no. 3; pp. 328 - 333
• Main Authors: Nakamura, Kazuya, Shirakura, Masayuki, Suzuki, Yasushi, Naito, Tadasuke, Fujisaki, Seiichiro, Tashiro, Masato, Nobusawa, Eri
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 12.01.2016; Elsevier Limited
• Subjects: Allergy and Immunology; Amino acids; Animals; Antibodies, Viral - blood; antiserum; avian influenza; Avian influenza A (H7N9) virus; Candidate vaccine virus; Centers for Disease Control and Prevention; chicken eggs; China; Clinical Trials, Phase II as Topic; Disease control; Ferrets; Genetics; hemagglutination; Hemagglutination Tests; hemagglutinins; human diseases; Humans; Influenza; Influenza A virus; Influenza A Virus, H7N9 Subtype - genetics; Influenza A Virus, H7N9 Subtype - immunology; Influenza Vaccines - administration & dosage; Influenza Vaccines - genetics; Influenza Vaccines - immunology; Influenza Vaccines - isolation & purification; Japan; Laboratories; Mortality; Mustela putorius furo; nucleotide sequences; pandemic; Pandemics; Plasmids; Reassortant Viruses - genetics; Reassortant Viruses - immunology; Reverse Genetics; Vaccines; Viral quasi-species; viruses; World Health Organization; China; Japan; HA; CVV; Candidate vaccine virus; MDCK cells; Avian influenza A (H7N9) virus; Viral quasi-species; hemagglutinin; Madin-Darby canine kidney cells; candidate vaccine virus

•We have developed a 6:2 reassortant vaccine virus for avian influenza A (H7N9).•The original virus stock, A/Anhui/1/2013 (H7N9), was a quasi-species.•A125T of NIIDRG-10.1 HA might enhance the growth ability of the virus. In April 2013, the first three fatal cases of human infection with an avian in...